EP Dec. 15, 2013: Challenges and Practical Benefits of Big Data and Cloud Computing
[The EmeraldPlanet TV] 12.15.13 Channel 10 TV "Challenges and Practical Benefits of Big Data and Cloud Computing in Foster Global Sustainable Development" Ou...
By: The EmeraldPlanet International Organization
See more here:
EP Dec. 15, 2013: Challenges and Practical Benefits of Big Data and Cloud Computing - Video
The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 80 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.
Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.
Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases. [More info...]
Read the original post:
Molecular Medicine - Graduate School of Biomedical Sciences ...
London, UK (PRWEB) December 20, 2013
Nowadays, molecular diagnostics in generic testing introduces advanced analytical techniques to the treatment and diagnosis of various generic disorders. The burgeoning growth in the market is propelled by considerable breakthroughs in proteomics and genomics, as well as by the ongoing development of microarray devices to measure different analytes within body tissues and blood. The range of the major recent developments includes but is not limited to the introduction and rapid uptake of cell-free fetal DNA prenatal testing, advancements in the development of personalised medicine, the integration of gene expression profiling and specialty labs into clinical practice, expansion of the installed base of automated instruments used for molecular testing and also the considerable progress of companion diagnostics for drug development.
At present, generic testing forms one of the most profitable segments of the overall molecular diagnostics space. The generic testing area has a huge growth potential, which is poised to be the major area of interest in the upcoming years.
Discounted research report Molecular Diagnostics in Genetic Testing drawn up by TriMark Publications (TriMark) has been recently published by Market Publishers Ltd.
Report Details:
Title: Molecular Diagnostics in Genetic Testing Published: November, 2013 Pages: 185 Price:US$ 3,060.00 http://marketpublishers.com/report/in_vitro_diagnostics/molecular_diagnostics/molecular-diagnostics-in-genetic-testing.html
The in-demand report presents a comprehensive guide to the emerging market for molecular diagnostics in generic testing globally and in the USA. It provides an in-depth assessment of this emerging field, offers a detailed analysis of its performance, estimates the size and growth potential of the molecular diagnostics in the genetic testing area. The research study contains a detailed examination of the major factors influencing the development of different market sectors, delves into the competitive environment and uncovers vital information on the performance of the leading companies engaged in the industry. The report characterises the regulative framework, describes the current market landscape and then thoroughly discusses the future growth prospects of molecular diagnostics in the generic testing universe.
Report Features & Benefits:
Other Discounted Research Studies by TriMark Include:
More insightful research reports by the publisher can be found at TriMark page.
Here is the original post:
San Diego-based genetic analysis company Sequenom Inc. announced that its subsidiary, the Sequenom Center for Molecular Medicine, has built another laboratory in North Carolina.
The new lab, in Raleigh-Durham, is currently processing patient samples with Sequenoms MaterniT21 PLUS tests. It said it can process 100,000 tests per year, increasing the companys total capacity to 300,000 test samples per year.
The MaterniT21 prenatal test evaluates whether a fetus has Down syndrome or other chromosomal abnormalities as early as 10 weeks of pregnancy.
We are excited about the opening in North Carolina of our third U.S.-based laboratory location, Sequenom president and COO William Welch said in a statement. Our investment in establishing this new presence on the East Coast will allow us to better meet the needs of health care providers by providing critical additional capacity and geographic backup needed to address the rapidly growing adoption of our testing services.
SDBJ Staff Report
Read the original:
Sequenom Center for Molecular Medicine Builds New Laboratory in North Carolina
Hollywood, CA (PRWEB) June 07, 2013
The producers of Impact Martin Sheen are pleased to announce a new series of reports exploring the nexus between technology and healthcare that is helping to bring new treatments for disease and illness into patient care.
Impact Martin Sheen is an independently produced television series airing in markets around the country on public television. The program is hosted by the legendary Martin Sheen, who is marking the start of his second half-century in American entertainment in 2013. Mr. Sheen has developed a reputation as one of Hollywoods most respected actors during a career that includes more than 60 film appearances.
Martin Sheen Impact is talking to researchers and other scientists about how molecular medicine is changing how doctors view disease and treatment. By exploring the building blocks of sickness, researchers are able to work on new treatments that attack disease at its very building blocks. In this new report, audiences will see how these new treatments are already showing promise for patients around the world who are suffering from a number of diseases.
The producers of Impact with Martin Sheen will distribute the new report in July. Check local listings for air times on public television and PBS affiliates in individual markets. For more information the producers can be contacted via the official website for the show at impactptv.com.
See original here:
Impact with Martin Sheen Exploring Molecular Medicine in a New Report
MU International Institute of Nano and Molecular Medicine
University of Missouri International Institute of Nano and Molecular Medicine Facility and Research Projects http://www.nanomed.missouri.edu/
By: MU HealthSystem
Read the rest here:
MU International Institute of Nano and Molecular Medicine - Video
MU International Institute of Nano and Molecular Medicine Groundbreaking
University of Missouri International Institute of Nano and Molecular Medicine Groundbreaking Ceremony http://www.nanomed.missouri.edu/
By: MU HealthSystem
Excerpt from:
MU International Institute of Nano and Molecular Medicine Groundbreaking - Video
Let #39;s Tell Him About Molecular Medicine at Phoenix Children #39;s
We know that the best stories you #39;ll ever tell often start with "Don #39;t Tell." But sometimes the most important legacy you #39;ll ever leave starts with "Let #39;s Te...
By: pchfoundation1
See the article here:
Let's Tell Him About Molecular Medicine at Phoenix Children's - Video
Newswise WASHINGTON The George Washington University (GW) Department of Biochemistry and Molecular Medicine will host Phillip A. Sharp, Ph.D., Nobel Laureate in Physiology or Medicine and Institute Professor at the Massachusetts Institute of Technology, to speak on The Biology and Synthesis of Non-coding RNAs, March 22 from noon to 1 p.m., as part of the departments Nobel Laureate Distinguished Lecture Series.
"Professor Sharp is a major contributor of this century to modern nucleic acid biology; his work not only discovered RNA splicing and processes that cause cancer, but also developed technology and methods to study complex regulatory interactions between protein factors and RNA or DNA. Thus, Dr. Sharp's contribution to medical sciences was a precursor to many pivotal discoveries from other laboratories. More recently, Dr. Sharp continues to reveal ever increasing significance of small RNAs in fine regulation of gene expression, an essential component of the living system. We, at the George Washington University, are very fortunate to have him share his perspective to our students, fellows, and faculty." said Rakesh Kumar, Ph.D., chair of the department of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences (SMHS).
The goal of the Nobel Laureate Distinguished Lecture Series is to bring todays leading researchers from all over the world to Washington, D.C. and to GW. Sharp, who won a Nobel Prize in Medicine or Physiology with a colleague in 1993 for their discoveries of discontinuous genes in mammalian cells, fundamentally changed scientists understanding of the structure of genes.
Sharps more than 380 scientific papers have earned him numerous cancer-research awards and presidential and national scientific-board appointments. He is an elected member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences, the Royal Society, and the American Philosophical Society. He is also the recipient of the Lasker Basic Medical Research Award, and the 2004 National Medal of Science. Sharp earned a B.A. degree from Union College, in Kentucky, and a Ph.D. in chemistry from the University of Illinois. In 1978 he co-founded Biogen (now Biogen Idec), and in 2002 he co-founded Alnylam Pharmaceuticals, an early stage therapeutics company.
Sharp is the third speaker to come to GW as part of the Nobel Laureate Distinguished Lecture Series. In February 2012, Aaron Ciechanover, M.D., Ph.D., who won the Nobel Prize in Chemistry in 2004 with two other scientists for describing how proteins are broken down by cell enzymes, spoke as part of the series. The lectures were launched by Ferid Murad, M.D., Ph.D., in September 2010. Murad, who won the Nobel Prize in Science or Medicine in 1998 for uncovering nitric oxides first biological effects, is now a University professor at GW and professor in SMHSs Department of Biochemistry and Molecular Medicine.
For more information, please contact Lisa Anderson at lisama2@gwu.edu or 202-994-3121.
###
About the School of Medicine and Health Sciences
Founded in 1825, the GW School of Medicine and Health Sciences (SMHS) was the first medical school in the nations capital and is the 11th oldest in the country. Working together in our nations capital, with integrity and resolve, the GW SMHS is committed to improving the health and well-being of our local, national and global communities. http://www.smhs.gwumc.edu.
Continued here:
GW Department of Biochemistry and Molecular Medicine to Host Nobel Laureate
Public release date: 5-Mar-2013 [ | E-mail | Share ]
Contact: Lena Raditsch lena.raditsch@embl.de 49-062-213-878-125 European Molecular Biology Laboratory
Today, the Nordic EMBL Partnership for Molecular Medicine celebrates two important milestones: the renewal of the partnership agreement for an extended period of 10 years, and the expansion of the Nordic EMBL network with the official opening of the Danish Research Institute of Translational Neuroscience (DANDRITE) at Aarhus University, which will become its Danish node.
The Nordic EMBL Partnership for Molecular Medicine was initiated in 2007 between the University of Oslo, Ume University, University of Helsinki and EMBL. As a result, three nodes were established in Norway, Sweden and Finland, each of which complements the research expertise of the other partners and, working closely with EMBL, aims to rise to challenges in biomedicine and to foster industry collaborations. In the five years since the launch of the partnership, the network has emerged as a strategic player in the molecular understanding of disease mechanisms in Europe, its impact and success recognised with today's signing of a renewed partnership agreement for an extended period of 10 years.
The research alliance is further strengthened by the growth of the partnership through the creation and inauguration of a Danish node. Complementing the research profile of the three existing nodes, DANDRITE will focus on conducting state-of-the-art research in the field of neuroscience. "We're excited to welcome Denmark as the fourth partner in the Nordic EMBL Partnership for Molecular Medicine. In a competitive national process, Aarhus University was selected to host the Danish node. The decision was made on the basis of the university's scientific expertise in the neurosciences and its research environment, which offer an excellent base for building a world-class collaborative institute like DANDRITE," says Iain Mattaj, Director General of EMBL.
The establishment of the Danish node was made possible through the Lundbeck Foundation, one of the largest private contributors to natural science research in Denmark, which funds the new centre jointly with Aarhus University. "The partnership with EMBL has arisen from the independent research approach, and DANDRITE has high ambitions, plenty of funding, independence and excellent infrastructure. Our ambition is to be the first with the latest ideas, rather than having to stand on the shoulders of others," says Poul Nissen, Director of DANDRITE and Professor of Protein Biochemistry at Aarhus University.
DANDRITE joins the Institute for Molecular Medicine Finland (FIMM, University of Helsinki), Centre for Molecular Medicine Norway (NCMM, University of Oslo), the Laboratory for Molecular Infection Medicine Sweden (MIMS, Ume University) and EMBL. All nodes benefit from continuous scientific and administrative support from EMBL, as well as from adopting aspects of the EMBL operational model, such as international recruitment, staff-turnover and the external review system.
###
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Read the rest here:
Denmark joins the Nordic EMBL Partnership for Molecular Medicine
The Institute of Molecular Medicine #39;s Role
http://www.ihealthtube.com http Professor Garth Nicolson founded the Institute. Here he discusses what that organization #39;s role is and some of the things it hopes to accomplish.
By: iHealthTube
See the rest here:
MANHASSET, N.Y., Feb. 12, 2013 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that New York University (NYU) immunology researcher Dan R. Littman, MD, PhD, will be the recipient of the first annual Ross Prize in Molecular Medicine, issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine.
(Photo: http://photos.prnewswire.com/prnh/20130212/DC58967)
Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology in the Skirball Institute of Biomolecular Medicine at NYU School of Medicine. He is a Howard Hughes Medical Institute investigator, and a member of both the National Academy of Sciences and the Institute of Medicine.
The Ross award, which includes a $50,000 prize, will be formally presented to Dr. Littman on June 24 at the New York Academy of Science in Manhattan, followed by an academic lecture by Dr. Littman and several other preeminent researchers.
The Ross Prize is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.
"A renowned immunologist, Dr. Littman has made seminal contributions in a number of scientific fields that advance our understanding of the immune system, HIV infections and autoimmune disease," said Feinstein Institute President Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "Dr. Littman and his colleagues discovered that HIV enters the body through what he terms a 'Trojan horse,' a specific type of immune cell, called an immature dendritic cell, which it then hijacks to attack other key cells of the immune system. Dr. Littman and his team have more recently discovered a means to control inappropriate autoimmune responses to bacteria that live naturally in the human digestive system."
Dr. Littman was selected by an awards committee comprised of:
The Ross Prize was made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY.
About Molecular Medicine
Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to: http://www.molmed.org
More here:
Molecular Medicine Awards 1st Annual Ross Prize to NYU Researcher
AUSTIN, Texas--(BUSINESS WIRE)--
Asuragen Inc., a leading molecular diagnostic company, today presented data on SuraSeq, its proprietary enrichment method for targeted next-generation sequencing (NGS), including recently published data in the Journal of Molecular Diagnostics, at the Molecular Medicine Tri-Conference in San Francisco. In addition to the published data, new data generated by Asuragen indicates that SuraSeq can assess up to three times the number of residual clinical FFPE DNA samples than other commercial cancer panels and methods, offering high depth, targeted NGS of oncogenes across a broad range of FFPE biopsies and improved analytical sensitivity compared to gold standard methods, such as Sanger sequencing.
There remains a paucity of published data for the application of targeted NGS to real-world cancer specimens, such as FFPE tumor biopsies. Our publication describes novel enrichment methods and quality control checks of nanogram quantities of FFPE and FNA DNA that were sequenced on complementary NGS platforms to provide accurate and sensitive detection of 'druggable' mutations, commented Gary Latham, Ph.D., Vice President, Research and Technology Development at Asuragen.
Implementation of next-generation sequencing into routine clinical practice requires compatibility with common tumor specimens, such as FFPE and fine-needle aspiration (FNA) biopsies, and validated processes for controls, samples, platforms, and data analysis pipelines. Asuragens study in the Journal of Molecular Diagnostics describes the validation of a two-step PCR enrichment workow (SuraSeq 500) that interrogates 540 known cancer-relevant variants from 16 oncogenes across distinct NGS chemistries (Illumina GAIIx and Ion Torrent PGM). The study included a rigorous characterization of the sequencing noise associated with FFPE samples, and the development of a novel bioinformatics pipeline to resolve this background to reveal low-level mutations. NGS variant calls from 38 residual clinical colorectal cancer FFPE specimens and 10 thyroid FNA specimens demonstrated an accuracy of 96.1% compared with Sanger sequencing, and 99.6% compared to Asuragens Signature KRAS mutation assay. Importantly, the publication also demonstrates the value of an orthogonal NGS platform in confirming cancer mutations identified from the primary NGS assay: Five driver mutations in the FFPE tumor cohort that were co-identified by the two independent NGS systems failed to be detected by Sanger sequencing, including variants that were confirmed using highly sensitive Signature mutation assays. SuraSeq offers high depth, targeted NGS of oncogenes across a broad range of FFPE biopsies and improved analytical sensitivity compared to last-generation, gold standard methods, such as Sanger sequencing, and can enable unprecedented versatility for mutation screening and confirmation to advance existing and emerging clinical applications. The SuraSeq technology is available through Asuragens Genomic Services laboratory, including three panels ranging from 250 to greater than 7,500 mutations of clinically relevant cancer genes (SuraSeq 200, 500, 7500).
About SuraSeq NGS Services
The use of genomic profiling to discover novel, disease-associated mutations has enormous potential to improve clinical decision-making. Asuragen specializes in targeted next-generation sequencing for sensitive detection of clinically actionable mutations from limiting DNA quantities. SuraSeq NGS Services are optimized to provide high resolution mutation profiling from challenging clinical biopsies through a combination of quantitative sample characterization and qualification, novel enrichment designs that specifically accommodate poor quality DNA, and innovative bioinformatics algorithms that call low abundance mutations with high sensitivity and positive predictive value.
About Asuragen
Asuragen is a molecular diagnostics company with a pioneering position in miRNA using genomics to drive better patient management through best-in-class clinical testing solutions. The Company uses a breadth of technologies and talent to discover, develop and commercialize diagnostic products and clinical testing services with efficiency and flexibility both internally and for our companion diagnostic partners. Today, Asuragens products, services and technologies drive countless patient management decisions across oncology, genetic disease and other molecular testing modalities. In the future, we envision the Companys development of miRNA-based clinical diagnostics will help transform medicine by improving clinical outcomes and health economics. For more information, visit http://www.asuragen.com.
Original post:
( University of Missouri-Columbia ) President Barack Obama named University of Missouri researcher M. Frederick Hawthorne as recipient of the National Medal of Science, the highest honor bestowed by the country to scientists. Hawthorne is the director of the International Institute of Nano and Molecular Medicine at the University of Missouri, as well as Curators' Distinguished Professor of ...
Go here to read the rest:
President Obama honors MU researcher with National Medal of Science
( University of Colorado Denver ) Researchers at the University of Colorado School of Medicine have figured out intimate details of how the hepatitis C virus takes over an invaded cell, a breakthrough that could point to way for new treatments for the virus.
Read the original post:
M. Frederick Hawthorne is the director of MU's International Institute of Nano and Molecular Medicine and was recently awarded the highest honor the government can grant to scientists, engineers and inventors. Read more
View original post here:
Scientists have offered a molecular-level explanation for how a Chinese herbal medicine tackles fever.
Go here to read the rest:
Opposing Viewpoints Live Radio For Television - Cloning
Is Cloning Ethical? Host - Lynn Harper Our guest #39;s key points - Once you let the genie out of the bottle you cannot put it back, it will only lead to the "slippery slope" of human reproductive cloning, states Bruno Leone. In contrast, Dr. Larry Goldstein says, we can restrict and control human reproductive cloning by laws and ethics standards. Guests Dr. Larry Goldstein, UCSD Professor of Cellular and Molecular Medicine, Investigator, Howard Hughes Medical Institute Bruno J. Leone, Professor of European Intellectual History SDSU, Author Lecturer on Cloning and Creationism vs EvolutionFrom:Vicki MikoViews:0 0ratingsTime:23:05More inEducation
Go here to read the rest:
Opposing Viewpoints Live Radio For Television - Cloning - Video
( Springer ) Springer will launch a new journal Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging. The bi-monthly publication will be the official journal of the Italian Association of Nuclear Medicine and Molecular Imaging as of 2013.
View post:
Springer launches new journal with the Italian Association of Nuclear Medicine and Molecular Imaging
From Genetic Discovery to Future Health
From Genetic Discovery to Future Health The European Network for Genetic and Genomic Epidemiology Heart failure, stroke, diabetes and obesity are a major public health concern in Europe. Our own behavior, like an unhealthy diet, too little physical activity or smoking, can influence the risk factors, but there #39;s more to the story. Causes for these disease are also partly genetic. How can we understand this complex interplay between genetic and behavioral causes for disease? Produced by Fast Facts With the support of ENGAGE The ENGAGE project has received research funds from The European Community #39;s Seventh Framework Programme (FP7/2007-2013), grant agreement HEALTH-F4-2007- 201413 Thanks to the European Network for Genetic and Genomic Epidemiology (ENGAGE), the researchers of ENGAGE, Isabelle Budin Ljsne (Norwegian Institute of Public Health), Huei-yi Shen (Institute for Molecular Medicine Finland) With images from: Obesity Research Unit, Helsinki University Central Hospital, Finland Made by: Marieke Aafjes Moira van Dijk 2012 In cooperation with Camera, editing compositing: Jonathan Massey / Persistent Vision Music: Daan van West Graphic design: SproetSFrom:FastFactsSciencetubeViews:8 0ratingsTime:07:58More inScience Technology
Follow this link: